Nonsteroidal anti-inflammatory drugs for dysmenorrhoea
Open accessThe DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Dysmenorrhoea is a common gynaecological problem consisting of painful cramps accompanying menstruation, which in the absence of any underlying abnormality is known as primary dysmenorrhoea. Research has shown that women with dysmenorrhoea have high levels of prostaglandins, hormones known to cause cramping abdominal pain. Nonsteroidal anti-inflammatory drugs (NSAIDs) are drugs that act by blocking prostaglandin production. They inhibit the action of cyclooxygenase (COX), an enzyme responsible for the formation of prostaglandins. The COX enzyme exists in two forms, COX-1 and COX-2. Traditional NSAIDs are considered 'non-selective' because they inhibit both COX-1 and COX-2 enzymes. More selective NSAIDs that solely target COX-2 enzymes (COX-2-specific inhibitors) were launched in 1999 with the aim of reducing side effects commonly reported in association with NSAIDs, such as indigestion, headaches and drowsiness. OBJECTIVES: To determine the effectiveness and safety of NSAIDs in the treatment of primary dysmenorrhoea. SEARCH METHODS: We searched the following databases in January 2015: Cochrane Menstrual Disorders and Subfertility Group Specialised Register, Cochrane Central Register of Controlled Trials (CENTRAL, November 2014 issue), MEDLINE, EMBASE and Web of Science. We also searched clinical trials registers (ClinicalTrials.gov and ICTRP). We checked the abstracts of major scientific meetings and the reference lists of relevant articles. SELECTION CRITERIA: All randomised controlled trial (RCT) comparisons of NSAIDs versus placebo, other NSAIDs or paracetamol, when used to treat primary dysmenorrhoea. DATA COLLECTION AND ANALYSIS: Two review authors independently selected the studies, assessed their risk of bias and extracted data, calculating odds ratios (ORs) for dichotomous outcomes and mean differences for continuous outcomes, with 95% confidence intervals (CIs). We used inverse variance methods to combine data. We assessed the overall quality of the evidence using GRADE methods. MAIN RESULTS: We included 80 randomised controlled trials (5820 women). They compared 20 different NSAIDs (18 non-selective and two COX-2-specific) versus placebo, paracetamol or each other. NSAIDs versus placeboAmong women with primary dysmenorrhoea, NSAIDs were more effective for pain relief than placebo (OR 4.37, 95% CI 3.76 to 5.09; 35 RCTs, I(2) = 53%, low quality evidence). This suggests that if 18% of women taking placebo achieve moderate or excellent pain relief, between 45% and 53% taking NSAIDs will do so.However, NSAIDs were associated with more adverse effects (overall adverse effects: OR 1.29, 95% CI 1.11 to 1.51, 25 RCTs, I(2) = 0%, low quality evidence; gastrointestinal adverse effects: OR 1.58, 95% CI 1.12 to 2.23, 14 RCTs, I(2) = 30%; neurological adverse effects: OR 2.74, 95% CI 1.66 to 4.53, seven RCTs, I(2) = 0%, low quality evidence). The evidence suggests that if 10% of women taking placebo experience side effects, between 11% and 14% of women taking NSAIDs will do so. NSAIDs versus other NSAIDsWhen NSAIDs were compared with each other there was little evidence of the superiority of any individual NSAID for either pain relief or safety. However, the available evidence had little power to detect such differences, as most individual comparisons were based on very few small trials. Non-selective NSAIDs versus COX-2-specific selectorsOnly two of the included studies utilised COX-2-specific inhibitors (etoricoxib and celecoxib). There was no evidence that COX-2-specific inhibitors were more effective or tolerable for the treatment of dysmenorrhoea than traditional NSAIDs; however data were very scanty. NSAIDs versus paracetamolNSAIDs appeared to be more effective for pain relief than paracetamol (OR 1.89, 95% CI 1.05 to 3.43, three RCTs, I(2) = 0%, low quality evidence). There was no evidence of a difference with regard to adverse effects, though data were very scanty.Most of the studies were commercially funded (59%); a further 31% failed to state their source of funding. AUTHORS' CONCLUSIONS: NSAIDs appear to be a very effective treatment for dysmenorrhoea, though women using them need to be aware of the substantial risk of adverse effects. There is insufficient evidence to determine which (if any) individual NSAID is the safest and most effective for the treatment of dysmenorrhoea. We rated the quality of the evidence as low for most comparisons, mainly due to poor reporting of study methods.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Brown, J., & Brown, S. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004142.pub2 · Cited by 82
RetractedMeasuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Meta-analyses involving cross-over trials: methodological issues
Elbourne, D. R., Altman, D. G., Higgins, J. P., Curtin, F., Worthington, H. V., & Vail, A. (2002) · International Journal of Epidemiology · doi:10.1093/ije/31.1.140 · Cited by 2,305
Hawkey, C. (1999) · The Lancet · doi:10.1016/s0140-6736(98)12154-2 · Cited by 1,173
Published by John Wiley & Sons Ltd
Modarresi, O. A. F., & Shakibaie, M. M. M. R. (2015) · Cited by 1,111
Nonsteroidal Antiinflammatory Drugs — Differences and Similarities
Oates, J. A., Wood, A. J. J., Brooks, P. M., & Day, R. O. (1991) · New England Journal of Medicine · doi:10.1056/nejm199106133242407 · Cited by 775
Latthe, P., Latthe, M., Say, L., Gülmezoglu, M., & Khan, K. S. (2006) · BMC Public Health · doi:10.1186/1471-2458-6-177 · Cited by 764
Primary Dysmenorrhea: Advances in Pathogenesis and Management
Dawood, M. Y. (2006) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000230214.26638.0c · Cited by 690
Non-Steroidal Anti-Inflammatory Drugs: Current Status and Rational Therapeutic Use
Hart, F. D., & Huskisson, E. C. (1984) · Drugs · doi:10.2165/00003495-198427030-00004 · Cited by 507
Carrasco, J. M., Lope, V., Pérez-Gómez, B., Aragonés, N., Suárez, B., López-Abente, G., Rodríguez-Artalejo, F., & Pollán, M. (2006) · BMC Public Health · doi:10.1186/1471-2458-6-1 · Cited by 435
Cited by
ESHRE guideline: management of women with endometriosis
Dunselman, G. A. J., Vermeulen, N., Becker, C., Calhaz-Jorge, C., D'Hooghe, T., De Bie, B., Heikinheimo, O., Horne, A. W., Kiesel, L., Nap, A., et al. (2014) · Human Reproduction · doi:10.1093/humrep/det457 · Cited by 2,211
Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective
Bindu, S., Mazumder, S., & Bandyopadhyay, U. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114147 · Cited by 1,920
Menstrual health: a definition for policy, practice, and research
Hennegan, J., Winkler, I. T., Bobel, C., Keiser, D., Hampton, J., Larsson, G., Chandra-Mouli, V., Plesons, M., & Mahon, T. (2021) · Sexual and Reproductive Health Matters · doi:10.1080/26410397.2021.1911618 · Cited by 449
Dysmenorrhea and related disorders
Bernardi, M., Lazzeri, L., Perelli, F., Reis, F. M., & Petraglia, F. (2017) · F1000Research · doi:10.12688/f1000research.11682.1 · Cited by 367
RETIRED: No. 345-Primary Dysmenorrhea Consensus Guideline
Burnett, M., & Lemyre, M. (2017) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/j.jogc.2016.12.023 · Cited by 332
Nonsteroidal anti-inflammatory drugs for pain in women with endometriosis
Brown, J., Crawford, T. J., Allen, C., Hopewell, S., & Prentice, A. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004753.pub4 · Cited by 308
Primary Dysmenorrhea: Pathophysiology, Diagnosis, and Treatment Updates
Itani, R., Soubra, L., Karout, S., Rahme, D., Karout, L., & Khojah, H. M. J. (2022) · Korean Journal of Family Medicine · doi:10.4082/kjfm.21.0103 · Cited by 280
Inflammatory Markers in Dysmenorrhea and Therapeutic Options
Barcikowska, Z., Rajkowska-Labon, E., Grzybowska, M. E., Hansdorfer-Korzon, R., & Zorena, K. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17041191 · Cited by 269
Sohail, R., Mathew, M., Patel, K. K., Reddy, S. A., Haider, Z., Naria, M., Habib, A., Abdin, Z. U., Razzaq Chaudhry, W., & Akbar, A. (2023) · Cureus · doi:10.7759/cureus.37080 · Cited by 239
Role of medical therapy in the management of uterine adenomyosis
Vannuccini, S., Luisi, S., Tosti, C., Sorbi, F., & Petraglia, F. (2018) · Fertility and Sterility · doi:10.1016/j.fertnstert.2018.01.013 · Cited by 231
Non-prescription (OTC) oral analgesics for acute pain - an overview of Cochrane reviews
Moore, R. A., Wiffen, P. J., Derry, S., Maguire, T., Roy, Y. M., & Tyrrell, L. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010794.pub2 · Cited by 174
Bruinvels, G., Goldsmith, E., Blagrove, R., Simpkin, A., Lewis, N., Morton, K., Suppiah, A., Rogers, J. P., Ackerman, K. E., Newell, J., et al. (2021) · British Journal of Sports Medicine · doi:10.1136/bjsports-2020-102792 · Cited by 173
Medical Management of Endometriosis
RAFIQUE, S., & DECHERNEY, A. H. (2017) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000292 · Cited by 173
Hennegan, J., Dolan, C., Steinfield, L., & Montgomery, P. (2017) · Reproductive Health · doi:10.1186/s12978-017-0339-9 · Cited by 83
Caruso, S., Iraci, M., Cianci, S., Vitale, S. G., Fava, V., & Cianci, A. (2019) · Journal of Pain Research · doi:10.2147/jpr.s207599 · Cited by 73
“Several women take on-demand non-steroidal anti-inflammatory drugs (NSAIDs) as first line agents to control their pelvic pain.(14) Hormonal treatment is adopted only after a specialist diagnoses endometriosis as the cause of the pelvic pain.”
BackgroundBurghaus, S., Schäfer, S. D., Beckmann, M. W., Brandes, I., Brünahl, C., Chvatal, R., Drahoňovský, J., Dudek, W., Ebert, A. D., Fahlbusch, C., et al. (2021) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1380-3693 · Cited by 69
Sinclair, J., Smith, C. A., Abbott, J., Chalmers, K. J., Pate, D. W., & Armour, M. (2020) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/j.jogc.2019.08.033 · Cited by 65
From pathogenesis to clinical practice: Emerging medical treatments for endometriosis
Clemenza, S., Sorbi, F., Noci, I., Capezzuoli, T., Turrini, I., Carriero, C., Buffi, N., Fambrini, M., & Petraglia, F. (2018) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2018.01.021 · Cited by 63
Conservative management of uterine adenomyosis: medical vs. surgical approach
Stratopoulou, C. A., Donnez, J., & Dolmans, M.-M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10214878 · Cited by 62
Aziato, L., Dedey, F., & Clegg-Lamptey, J. N. A. (2014) · Reproductive Health · doi:10.1186/1742-4755-11-58 · Cited by 62
De Leo, V., Cagnacci, A., Cappelli, V., Biasioli, A., Leonardi, D., & Seracchioli, R. (2019) · Minerva Ginecologica · doi:10.23736/s0026-4784.19.04384-3 · Cited by 23
Metadata
- Authors
- Marjoribanks, J., Ayeleke, R. O., Farquhar, C., & Proctor, M.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2015-07-30
- Volume
- 2015
- Issue
- 7
- Pages
- CD001751-CD001751
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2109711640
- Cited by
- 562
- References
- 76
- FWCI
- 33.32
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.